BioMarin
Trade BioMarin 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMRN
BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.
BMRN Key Statistics
Stock Snapshot
As of today, BioMarin(BMRN) shares are valued at $66.53. The company's market cap stands at 12.88B, with a P/E ratio of 179.37.
On 2026-09-05, BioMarin(BMRN) stock moved within a range of $65.47 to $66.64. With shares now at $66.53, the stock is trading +1.6% above its intraday low and -0.2% below the session's peak.
Trading activity shows a volume of 1.23M, compared to an average daily volume of 1.82M.
The stock's 52-week range extends from a low of $49.26 to a high of $70.98.
The stock's 52-week range extends from a low of $49.26 to a high of $70.98.
BMRN News
BioMarin Pharmaceutical (BMRN) is back in focus after a settlement and license agreement with Ascendis Pharma over YUVIWEL turned a direct achondroplasia compet...
New insider activity at BioMarin Pharmaceutical ( (BMRN) ) has taken place on September 3, 2026. Executive Vice President and Chief Legal Officer George Eric D...
For BioMarin Pharmaceutical BMRN, the FDA approval of Ascendis Pharma’s ASND Yuviwel in February had created a problem — a new entrant targeting the same achond...
Analyst ratings
77%
of 30 ratingsMore BMRN News
CASI Pharmaceuticals ( (CASIF) ) has provided an update. On August 31, 2026, CASI Pharmaceuticals sold its equity interests in Alesta Therapeutics B.V. to BioM...
BioMarin Pharmaceutical ( (BMRN) ) just unveiled an announcement. BioMarin Pharmaceutical Inc. has completed the acquisition of Dutch biotech company Alesta Th...
BioMarin Pharmaceutical (BMRN) said that it completed the previously announced agreement to acquire Alesta Therapeutics. The acquisition will strengthen BioMari...
Cantor Fitzgerald raised the firm’s price target on BioMarin (BMRN) to $86 from $85 and keeps an Overweight rating on the shares after the company reached a set...
Ascendis Pharma ( (ASND) ) has shared an announcement. On August 31, 2026, Ascendis Pharma announced a binding term sheet for a global settlement and license a...
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $105.00. Akash Tewari has gi...
H.C. Wainwright lowered the firm’s price target on Ascendis Pharma (ASND) to $344 from $345 and keeps a Buy rating on the shares. The Yuviwel royalty settlement...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.